Background Biogen and Denali halted the mid‑stage clinical trial because the primary efficacy endpoint did not achieve statistical significance in a study aimed at slowing Parkinson’s disease progression. ## Patient‑Cohort Re‑targeting Denali announced that, despite the termination, it will conduct separate experiments focusing on Parkinson’s sub‑populations with specific genetic variants or clinical phenotypes. ## Partnership Impact The outcome highlights the risk inherent in the companies’ neurodegenerative collaboration and could influence future co‑development agreements and funding allocations. ## Market Implications The Parkinson’s therapeutic market is worth several billion dollars annually; this trial failure may prompt a reassessment of competitors’ pipelines and could temporarily dampen investment flows.